Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES).

Suppr

超能文献

作者信息

Mandell Lionel A

机构信息

McMaster University, Hamilton, Ontario, Canada.

出版信息

Diagn Microbiol Infect Dis. 2002 Sep;44(1):65-7. doi: 10.1016/s0732-8893(02)00444-3.

DOI:10.1016/s0732-8893(02)00444-3

PMID:12376034

Abstract

摘要

相似文献

Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES).

Diagn Microbiol Infect Dis. 2002 Sep;44(1):65-7. doi: 10.1016/s0732-8893(02)00444-3.

Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):127-8. doi: 10.1016/s0732-8893(02)00450-9.

Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):85-91. doi: 10.1016/s0732-8893(02)00447-9.

Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):117-25. doi: 10.1016/s0732-8893(02)00465-0.

Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):109-16. doi: 10.1016/s0732-8893(02)00458-3.

An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers.

Braz J Infect Dis. 2003 Feb;7(1):62-8. doi: 10.1590/s1413-86702003000100007. Epub 2003 Dec 2.

Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.

Otolaryngol Head Neck Surg. 2002 Sep;127(3):182-9. doi: 10.1067/mhn.2002.127590.

Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).

J Chemother. 2004 Apr;16 Suppl 2:11-4. doi: 10.1080/1120009x.2004.11782367.

Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly.

J Infect Chemother. 2005 Dec;11(6):274-7. doi: 10.1007/s10156-005-0410-2.

Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):93-100. doi: 10.1016/s0732-8893(02)00448-0.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES).

Diagn Microbiol Infect Dis. 2002 Sep;44(1):65-7. doi: 10.1016/s0732-8893(02)00444-3.

Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):127-8. doi: 10.1016/s0732-8893(02)00450-9.

Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):85-91. doi: 10.1016/s0732-8893(02)00447-9.

Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):117-25. doi: 10.1016/s0732-8893(02)00465-0.

Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):109-16. doi: 10.1016/s0732-8893(02)00458-3.

An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers.

Braz J Infect Dis. 2003 Feb;7(1):62-8. doi: 10.1590/s1413-86702003000100007. Epub 2003 Dec 2.

Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.

Otolaryngol Head Neck Surg. 2002 Sep;127(3):182-9. doi: 10.1067/mhn.2002.127590.

Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).

J Chemother. 2004 Apr;16 Suppl 2:11-4. doi: 10.1080/1120009x.2004.11782367.

Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly.

J Infect Chemother. 2005 Dec;11(6):274-7. doi: 10.1007/s10156-005-0410-2.

Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.

Diagn Microbiol Infect Dis. 2002 Sep;44(1):93-100. doi: 10.1016/s0732-8893(02)00448-0.